{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-132586","form_type":"8-K","ticker":null,"cik":"0001567514","company_name":"Intra-Cellular Therapies, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.002627+00:00","generated_at":"2026-06-02T18:20:38.113134+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Intra-Cellular Therapies Q1: $144.8M CAPLYTA sales (+53% YoY), loss narrows; Ph3 MDD success","bullets":["Net product sales of CAPLYTA $144.8M, up 53% from $94.7M YoY; net loss $15.2M vs $44.1M.","Positive Phase 3 Study 501 results: lumateperone adjunctive MDD met primary (MADRS, p<0.0001) and key secondary endpoints.","FY 2024 guidance reiterated: CAPLYTA sales $645-$675M, SG&A $450-$480M, R&D $215-$240M.","Completed $543M net public offering of ~7.9M shares in April 2024; cash $477.4M at Q1 end.","Expect to report Study 502 topline results late Q2 2024; sNDA filing planned H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-132586","json":"https://secwatch.observer/filing/0001193125-24-132586.json","markdown":"https://secwatch.observer/filing/0001193125-24-132586.md","text":"https://secwatch.observer/filing/0001193125-24-132586.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567514/000119312524132586/0001193125-24-132586-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567514/000119312524132586/d826948d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:20:38.113134+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a8fcd8460b6ccd9eb6a8831c015ef2a81ca6ee97","claim":"Intra-Cellular Therapies, Inc. reported the first quarter ended March 31, 2024 results: revenue $144.9 million, net income Net loss for the first quarter of 2024 was $15.2 million. Guidance reaffirmed.","evidence_excerpt":"Total revenues were $144.9 million for the first quarter of 2024, compared to $95.3 million for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567514/000119312524132586/0001193125-24-132586-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$144.9 million"},{"label":"Net income","value":"Net loss for the first quarter of 2024 was $15.2 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}